Methods, compounds, and compositions for the treatment of angiotensin-related diseases
US-9732074-B2 · Aug 15, 2017 · US
Methods for treating or limiting development of cardiovascular disease-related neurological disorders
US11833148B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11833148-B2 |
| Application number | US-201917053984-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 10, 2019 |
| Priority date | May 11, 2018 |
| Publication date | Dec 5, 2023 |
| Grant date | Dec 5, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are methods for treating or limiting development of cardiovascular disease-related neurological disorders by administering a compound of general formula (I), as defined herein.
First claim
Opening claim text (preview).
We claim: 1. A method for increasing cognitive function in a subject having a cardiovascular disease-related neurological disorder, comprising administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount effective to increase the subject's cognitive function of a compound selected from compound 7 and compound 10: or a pharmaceutically acceptable salt thereof, and wherein the cardiovascular disease is left-ventricular hypertrophy, and wherein the cardiovascular disease-related neurological disorder is cognitive decline or Alzheimer's disease. 2. The method of claim 1 , wherein the cardiovascular disease-related neurological disorder is Alzheimer's. 3. The method of claim 1 , wherein the compound is compound 7.
Assignees
Inventors
Classifications
- A61K31/496Primary
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
- A61K31/4439Primary
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
Antihypertensives · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Sulfur atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11833148B2 cover?
- Disclosed herein are methods for treating or limiting development of cardiovascular disease-related neurological disorders by administering a compound of general formula (I), as defined herein.
- Who is the assignee on this patent?
- Univ Arizona
- What technology area does this patent fall under?
- Primary CPC classification A61K31/496. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).